開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
英國首相發言人:俄羅斯對烏克蘭火車的攻擊不會動搖美國的立場。
2026-09-14
英國首相發言人:俄羅斯對烏克蘭火車的攻擊不會動搖美國的立場。
返回
其他消息
2026-09-14
Tradeweb data showed eurozone government bond yields edged up, with the 10-year German bund yield touching a 15-year high of 3.532% in early trade. Signs of economic resilience, elevated oil prices and escalating Middle East tensions raised inflation concerns and pushed yields higher. After the ECB's rate hike last week, market focus shifts to the Fed's decision this week; a rate increase is possible but not certain.
Tradeweb data showed eurozone government bond yields edged up, with the 10-year German bund yield touching a 15-year high of 3.532% in early trade. Signs of economic resilience, elevated oil prices and escalating Middle East tensions raised inflation concerns and pushed yields higher. After the ECB's rate hike last week, market focus shifts to the Fed's decision this week; a rate increase is possible but not certain.
2026-09-14
At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.
At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.
Chat with us
, powered by
LiveChat